OrganOx

What OrganOx does

OrganOx is a UK-headquartered medical technology company that develops and commercializes normothermic machine perfusion (NMP) platforms for organ preservation and assessment. Founded in 2008 as a spin-out from the University of Oxford by Professors Peter Friend and Constantin Coussios, the company built the metra system — the first commercial NMP platform for liver transplantation — which maintains donor livers in a metabolically active, oxygenated, blood-based perfusate at normal body temperature. The metra platform integrates a centrifugal pump, self-regulating oxygenator, soft-shell perfusate reservoir, in-line blood gas analyzer, automated medication infusion driver, and touchscreen interface, and has been used in over 10,000 liver transplants globally. OrganOx holds FDA approval (granted 2021), CE Mark, UKCA, Australian TGA approval, and Health Canada licensure, with additional FDA clearance for air transport and an IND clearance for an investigational Extracorporeal Liver Cross-Circulation (ELC) system co-developed with eGenesis.

The company generates revenue primarily through sales of the metra capital equipment, associated consumables, and service contracts to transplant centers and hospitals, supplemented by training and certification programs for clinical teams. Go-to-market is enterprise field sales direct to transplant centers across the U.S., U.K., EU, Australia, and Canada, augmented by channel partnerships with organ procurement organizations (OPOs) and recovery/logistics providers such as ProCure On-Demand and Strata Critical Medical. The clinical value proposition — backed by the COPE European randomized trial — is up to 50% lower graft injury, up to 50% reduction in organ discard rates, and ~20% increase in transplant volume versus static cold storage.

In October 2025, Terumo Corporation completed a $1.5 billion acquisition of OrganOx, making it a wholly owned subsidiary (also referenced as Terumo Organ Technologies). The deal followed a $160 million private placement in early 2025 and represented one of the largest UK medtech exits. Post-acquisition, OrganOx continues to operate from its Oxford headquarters with a Madison, New Jersey U.S. presence, and appointed Naoya Iwata, formerly Chief of Staff to Terumo's CEO, as CEO & President effective June 1, 2026, reflecting the parent's intent to leverage Terumo's global infrastructure for further commercial and clinical expansion of the platform.

Name

OrganOx

Legal name

OrganOx Limited

Website

https://organox.com

Company type

Private

Founded year

2008

Operating status

Acquired

Headcount range

101–250 employees

Short description

OrganOx develops and commercializes the metra normothermic machine perfusion platform, the first commercial NMP system for liver transplantation, sold to transplant centers, hospitals, and OPOs across the U.S., U.K., EU, Australia, and Canada. Acquired by Terumo Corporation for $1.5 billion in October 2025.

Ownership category

akta.pro rank

Product category

Organ Transplantation Medical Devices

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Transplant Hepatology (HLAKAEAK)

akta.pro secondary industries

Hepatology & Liver Disease (HLAKAEAB), Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Organ preservation technology
• Machine perfusion devices
• Liver transplantation equipment
• Medical device manufacturing
• Transplant center supplies

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. metra® Device Sales and Service: OrganOx generates revenue through the sale and service of its metra® normothermic machine perfusion device to transplant centers and hospitals. The device is a capital equipment with associated consumables and support services.
2. Training and Certification Services: OrganOx provides education and certification through exclusive training programs for clinical teams using the metra® platform, supporting transplant centers and organ procurement organizations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

OrganOx develops, manufactures, and sells the metra normothermic machine perfusion (NMP) platform, the world's first NMP device for liver transplantation. The system keeps donor livers metabolically active outside the body by perfusing them with oxygenated, warmed blood-based perfusate at near-physiological pressures, extending preservation time and enabling functional viability assessment prior to transplant. The company also offers clinical training and certification services for transplant centers, and is developing an investigational Extracorporeal Liver Cross-circulation (ELC) System in partnership with eGenesis for acute-on-chronic liver failure treatment.

Product overview

OrganOx offers a platform-based product portfolio centered on the metra normothermic machine perfusion (NMP) technology. The core product is the OrganOx metra, the world's first NMP platform for liver transplantation, which maintains donor organs in a metabolically active state outside the body. The platform includes supporting applications like metra Assist and mApp. An investigational extension is the Extracorporeal Liver Cross-circulation (ELC) System, co-developed with eGenesis for acute-on-chronic liver failure treatment using genetically engineered porcine livers. The technology has received regulatory approvals in the U.S. (FDA), Europe (CE Mark), UK (UKCA), Australia, and Canada (licensed).

Differentiator

Problem solved

Functional benefit

Brands

• metra: The OrganOx metra is a normothermic machine perfusion (NMP) platform technology for liver transplantation that keeps donor livers metabolically active outside the body, enabling extended preservation and functional assessment prior to transplant.

Products and services

• OrganOx metra The OrganOx metra is a normothermic machine perfusion (NMP) platform for liver transplantation. It keeps donor livers metabolically active outside the body by continuously perfusing them with oxygenated blood-based perfusate, medications, and nutrients at normal body temperature, enabling extended preservation times and functional viability assessment prior to transplant. Sold as capital equipment to hospitals, transplant centers, and organ procurement organizations.
• Extracorporeal Liver Cross-circulation (ELC) System An investigational liver support system combining OrganOx's automated NMP technology with a patient support accessory device. Co-developed with eGenesis to treat patients with acute-on-chronic liver failure using genetically engineered human-compatible porcine livers (EGEN-5784). Currently in Phase 1 clinical trials under FDA IND clearance.
• Training and Certification Services Education, clinical training, and certification programs for clinical teams using the metra platform. OrganOx provides exclusive training to support transplant centers and organ procurement organizations deploying the metra system.

Quantifiable outcome

• 50% lower graft injury vs static cold storage despite 54% longer preservation time
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• Strata Critical MedicalcoreChannel Partner/ Reseller/ Distributor · 18 September 2025Partnership with Strata Critical Medical (NASDAQ:SRTA) for 24/7 device-to-donor support across the U.S., enabling air and ground transportation of donor livers on the metra® device. FDA approval for air transport enables nationwide coverage.
• Terumo CorporationcoreStrategic or Co-development Partner · 25 August 2025Acquired OrganOx for approximately $1.5 billion, making OrganOx a wholly owned subsidiary. Transaction completed October 30, 2025. Positions OrganOx to leverage Terumo's global infrastructure for expansion.
• ProCure On-DemandcoreChannel Partner/ Reseller/ Distributor · 17 March 2025Partnership to expand access for liver transplants by combining OrganOx's NMP technology with ProCure's advanced surgical, perfusion, preservation, and logistics solutions. OrganOx supports ProCure's clinical teams through education and certification.
• eGenesiscoreStrategic or Co-development Partner · 12 November 2024Exclusive clinical co-development agreement to advance a liver support system combining OrganOx's NMP technology with eGenesis's human-compatible, genetically engineered porcine livers (EGEN-5784) for treatment of patients with acute-on-chronic liver failure. The FDA cleared the IND application in April 2025 for Phase 1 clinical trials.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• TransMedics: TransMedics develops the Organ Care System (OCS), a portable ex-vivo perfusion and monitoring system for lung, heart, and liver transplantation. It is the most direct competitor to OrganOx's metra in liver NMP, serving the same transplant centers with a competing clinical evidence base.
• XVIVO Perfusion: XVIVO Perfusion provides machine perfusion technology for organ transplantation, with established leadership in lung perfusion (XPS and LS) and expanding into liver and other organ preservation. Directly comparable to OrganOx as a perfusion technology peer serving transplant centers globally.
• Organ Recovery Systems: Organ Recovery Systems manufactures the LifePort Kidney Transporter, a machine perfusion device for kidney preservation, and has expanded into liver preservation. Directly comparable to OrganOx as a perfusion technology peer for solid organ transplantation, with overlapping transplant center customer base.
• Bridge to Life: Bridge to Life manufactures and distributes cold storage preservation solutions (Belzer UW and Custodiol) used in organ transplantation. Comparable to OrganOx as the dominant provider of static cold storage solutions, which metra directly competes against in the same transplant center market.
• Preservation Solutions: Preservation Solutions develops and manufactures organ preservation solutions and perfusion equipment used in transplantation procedures. Comparable to OrganOx as a supplier of organ preservation technology to transplant centers and OPOs.
• Waters Medical Systems: Waters Medical Systems (now part of the broader transplant ecosystem) provides organ preservation and perfusion technologies for kidney and liver transplantation. Comparable to OrganOx as a perfusion equipment manufacturer serving transplant centers.

Emerging players

• Paragonix Technologies: Paragonix Technologies develops hypothermic organ preservation and transport devices for heart, lung, liver, and kidney transplantation. Comparable to OrganOx as an emerging organ preservation technology peer focused on donor organ transport logistics for transplant centers.

Others

• eGenesis: eGenesis develops human-compatible genetically engineered porcine organs for xenotransplantation and is OrganOx's exclusive clinical co-development partner for the ELC system treating acute-on-chronic liver failure. Comparable as a strategic partner in the xenotransplantation and liver failure treatment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/organ_ox
• Facebookfacebook.com/normothermic1
• LinkedInlinkedin.com/company/organox

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds9 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrganOx